Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916694 | 1.00 | GPR119 (0.47) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL20135523 | 0.89 | GPR119 (0.48) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL20134910 | 0.89 | GPR119 (0.48) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL29688701 | 0.89 | GPR119 (0.48) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL20134912 | 0.89 | GPR119 (0.48) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL29688824 | 0.89 | GPR119 (0.48) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL30046432 | 0.87 | CHRM1 (0.51) | GPR119MAP4K4HDAC1TRPV1CHRM1 | |
| SCHEMBL30045559 | 0.87 | CHRM1 (0.51) | GPR119MAP4K4HDAC1TRPV1CHRM1 | |
| SCHEMBL2419857 | 0.86 | GPR119 (0.45) | GPR119MAP4K4HDAC1TRPV1SUV39H2 | |
| SCHEMBL18838015 | 0.85 | GPR119 (0.44) | GPR119MAP4K4HDAC1SUV39H2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824490-A4 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORP (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1824490-A1 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006065872-A1 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | PRLHR, GPR27, GPR68 | GPR119 52/4885MAP4K4 1605/4885HDAC1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.